We have reported that serum granulocyte colony-stimulating factor (G-CSF) and interleukin-6 (IL-6) levels rise in patients with chemotherapy-induced myelosuppression. The aim of the present study was to determine whether other cytokines that function at different hematopoietic stages also fluctuate during chemotherapy-induced myelosuppression and whether the extent of cytokine level fluctuations correlate with myelosuppression severity. Fifteen patients participated in the study. Serum levels of stem cell factor (SCF), interleukin (IL)-1a, IL-6, IL-3, granulocytemacrophage CSF (GM-CSF) and G-CSF were analyzed before chemotherapy and during the myelosuppressive stage and correlations between cytokine levels and myelosuppression severity were examined. The results showed that both serum G-CSF and IL-6 levels rose in patients with chemotherapy-induced myelosuppression. The prechemotherapy serum G-CSF and IL-6 levels correlated well with their respective elevated levels during the myelosuppressive stage. The myelosuppression severity also correlated well with the extent of serum G-CSF level elevation. The serum IL-6 and G-CSF levels during the myelosuppressive stage correlated significantly. Serum SCF levels did not fluctuate significantly during myelosuppression, and IL-1, IL-3 and GM-CSF were rarely detected in serum even after chemotherapy. In the present study, the roles of IL-1a, SCF, IL-3 and GM-CSF chemotherapy-induced myelosuppression were not clear.
Introduction
Cytokines regulate proliferation, differentiation and functional activation of hematopoietic cells of multiple lineages. It has been reported that the serum granulocyte colony-stimulating factor (G-CSF) level rises, peaks just prior to recovery from the neutrophil nadir and decreases as the circulating neutrophil count increases in patients receiving chemotherapy." We found that serum interleukin-6 (IL-6) level elevations occurred before serum G-CSF level increased in patients with chemotherapy-induced myelosuppression. 2 ' Extensive clinical trials have demonstrated the efficacy of human recombinant G-CSF (rhG-CSF) or granulocyte macrophage CSF (GM-CSF) for ameliorating chemotherapy-induced Received: July 6, 1995 Accepted: September 11, 1995 For reprints and all correspondence: Yuh-Min Chen, Chest Department, Veterans' General Hospital-Taipei, Shin-pai, Taipei, Taiwan, ROC myelosuppression or accelerating recovery from it.
3>4) Furthermore, several phase I/II clinical trials have also utilized IL-aa, IL-6, and IL-3 for marrow support and the use of combinations of these cytokines concurrently or sequentially has been studied in vitro and in v/vo. 4 " 10 ' Stem cell factor (SCF), known as the c-kit ligand, is a recently identified pleiotrophic growth factor, which may play a role in the early stages of hematopoiesis, whereas IL-la, IL-6 and IL-3 act in the early or intermediate stages, followed by GM-CSF and G-CSF later on in hematopoiesis. 311 ' It was considered to be of great interest to examine the serum levels of these cytokines in patients during chemotherapy-induced myelosuppression. The objectives of this study were to determine whether serum SCF, IL-la, IL-3 and GM-CSF levels rose in parallel with those of IL-6 and G-CSF in chemotherapy-induced myelosuppression. The correlations between these cytokine levels and myelosuppression severity were also examined.
Materials and Methods

Patients
The study was performed on blood samples from 15 patients (11 male, 4 female) with solid tumors (Table I) . Their mean age was 56.8 year (range: 17-72), none of them had autoimmune disease, they were all free from infection during the study period, and 2 had a leukemoid reaction before chemotherapy. No immunotherapy or radiotherapy was given during the study. Most patients received intravenous cisplatin and etoposide treatment for 3 days.
Blood Sample Preparation
Peripheral blood samples were taken from all the patients before chemotherapy and during the myelosuppressive stage. Each blood sample was divided into 2 portions: one for the complete blood count analysis and the other for cytokine analysis. The latter was coagulated in the refrigerator at 4°C, centrifuged at 1000 xg for 15 min, the serum was collected and 0.25-ml aliquots in microcentrifuge tubes were stored at -70°C. Aliquots were used once only for the test and were not subjected to repeated freeze-thaw cycles.
Cytokine Measurement
Serum SCF, IL-la, IL-6, IL-3, GM-CSF and G-CSF levels were assayed in duplicate using a commercial ELISA kit (Quantikine; R & D systems, Inc., Minneapolis, WI). The Quantikine immunoassay is a solid phase ELISA method that employs the quantitative 'sandwich' enzyme immunoassay technique. The minimum detectable concentrations of SCF, IL-la, IL-6, IL-3, GM-CSF. and G-CSF in serum were 4.0, 0.2, 0.7, 8.9, 2.8 and 10.9 pg/ml, respectively. All the samples were assayed within one month of collection.
Statistical Analysis
The Wilcoxon matched-pairs signed-ranks test was performed to determine whether the serum cytokine levels in individual myelosuppressed patients changed significantly compared with prechemotherapy levels.
Then, the patients were classified into 4 groups according to the severity of their myelotoxicity and the mean ± standard deviation and median serum cytokine levels in each group were calculated. Statistical evaluation of group data was performed using 2-step methods. ANOVA was used initially to compare cytokine levels among groups. If ANOVA showed a significant difference, pairwise comparisons among groups were performed using the Tukey-B test for multiple comparison adjustment.
Differences between cytokine levels were considered significant if the P value was less than 0.05 after multiple comparison adjustment. Correlations between cytokine levels before chemotherapy and during the myelosuppressive stage were also evaluated.
Results
Cytokine Levels
The G-CSF levels of all 15 patients were determined prechemotherapy and during myelosuppression and they all had elevated G-CSF levels during the latter. Serum SCF data were available for all the patients before chemotherapy and for 14 during the myelosuppressive stage, when 10 of the 14 had elevated serum SCF levels. Serum IL-6 levels were obtained before chemotherapy and during the myelosuppressive for 14 patients, in 10 of whom they were elevated during the myelosuppressive stage, whereas those in the remaining 4 showed no obvious changes. Of the 14 patients whose serum IL-la levels were determined before chemotherapy and during the myelosuppressive stage, only 3 had detectable serum IL-la levels. The serum IL-3 levels of 12 patients were measured before chemotherapy and during the myelosuppressive stage, but IL-3 was detected in none of them. Thirteen patients' sera were assayed for GM-CSF, which was detectable in only 1 before chemotherapy and during the myelosuppressive stage (Table I ).
Significant Elevations of Serum Cytokine Levels during Myelosuppession
The serum SCF, IL-6 and G-CSF level data were analyzed using the Wilcoxon matched-pairs signedranks test, which showed significant elevations of serum IL-6 (P=0.008) and G-CSF (P = 0.0007), but not of serum SCF (P = 0.14), levels in individual patients during the myelosuppressive stage.
More Severe Myelosuppression with Higher Serum Cytokine Levels
ANOVA and the Tukey-B test were performed to determine whether more severe myelosuppression was associated with higher serum cytokine levels. The patients were grouped according to the Eastern Cooperative Oncology Group (ECOG) criteria for myelosuppression. Significantly higher serum G-CSF level elevations were observed in patients with grade 4 than grades 2 or 3 leukocyte toxicity (Table III) . As only 1 patient each showed platelet toxicity of grades 1, 2, 3 and 4, the platelet count was not used for this analysis. The serum SCF and IL-6 levels in patients with different grades of leukocyte toxicity did not differ significantly. 
58 U u^. *, unit of cytokine level is pg/ml; WBC, white blood cell count (/mm 3 ); PLT, platelet count (xl0 J /mm 3 ); M, male; F, female; A, before chemotherapy; B, during myelosuppression; ND, not done; U, undetectable or below minimal detectable concentrations; MUO, metastases from unknown primary; SCLC, small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; CEO, cyclophosphamide, epirubicin, oncovin; EPOCH, VP-16, prednisolone, oncovin, cyclophosphamide, adriamycin. 
Correlations between Cytokine Levels before Chemotherapy and during Myelosuppression
The prechemotherapy serum SCF, IL-6, and G-CSF levels correlated with their respective serum levels during myelosuppression and this correlation was strongest for IL-6 (Table III) . The white blood cell and platelet counts during myelosuppression correlated with the serum G-CSF levels during myelosuppression, indicating that those who suffer from more severe myelosuppression will have higher serum G-CSF levels. The serum IL-6 and G-CSF WBC Counts /mm 3 levels during myelosuppression also correlated significantly, indicating that patients with high serum IL-6 levels will also have high serum G-CSF levels (Figs. 1-3 ).
Discussion
Chemotherapy-induced myelosuppression has been found to be associated with raised serum G-CSF and IL-6 levels.
-
2) Human recombinant G-CSF, GM-CSF and IL-3 are frequently prescribed to prevent chemotherapy-induced myelosuppression or to accelerate recovery from it.
3>4) Artificial supplementation of the endogenous production of these cytokines accelerates the restoration of hematological homeostasis. G-CSF acts as an endocrine growth factor or as a stress hormone to increase the blood neutrophil count and this function has also been described in patients with infectious diseases.'•
12>
Chronological changes in the serum levels of endogenous cytokines other than G-CSF in chemotherapy-induced myelosuppression have been reported rarely. In our study we found no detectable IL-3 in serum either before chemotherapy or during the myelosuppressive stage. IL-la and GM-CSF were also rarely detectable in serum or their levels underwent no obvious changes during the myelosuppressive state. In previous studies, 11 ' 13) detectable GM-CSF and G-CSF levels were found in organ extracts and conditioned media of normal' and endotoxin-injected mice, whereas GM-CSF was rarely detectable in peripheral blood and IL-3 was found neither in organ extracts nor peripheral blood. Our negative IL-la, IL-3 and GM-CSF serum level results suggest that IL-la, IL-3, and GM-CSF do not play very important roles as endocrine hormones in accelerating myeloid recovery. Whether detectable levels of these three cytokines are present in the local hematopoietic milieu and act as paracrine hormones in humans is unknown. Previous and our studies demonstrated elevated serum IL-6 and G-CSF levels during myelosuppression and infection. •• *• 10 -n - 14) Therefore, serum IL-6 and G-CSF appeared to be the most important of the endocrine factors tested for accelerating myeloid recovery.
To our knowledge, no studies on SCF levels in patients with chemotherapy-induced myelosuppression have been conducted, 15 -I6) although in vitro studies using SCF in combination with GM-CSF or IL-3 to stimulate proliferation of cell lines have been reported.
-
17) The behavior of proliferating stem cells in the bone marrow, which may express c-kit (SCF receptor), could be regulated by membrane-bound SCF present on surrounding stromal cells. 18 ' This finding was substantiated by the observation that SCF receptors and SCF interaction did not appear to be essential for the initiation of hematopoiesis and the self-renewal of (at least) fetal hematopoietic stem cells in vitro. m Therefore, SCF may assist, but is not an essential factor, in proliferation and differentiation of stem cells. As the serum SCF levels did not rise significantly, the role of SCF in the circulation was unclear despite the fact that the majority of our patients tended to have raised serum SCF levels during the myelosuppressive stage.
Our data showed that patients with higher grades of myelosuppression had significantly higher serum G-CSF levels. The serum G-CSF and IL-6 levels correlated significantly during the myelosuppressive stage and was probably attributable to stimulation of G-CSF production by IL-6. We believe the serum G-CSF level increase during myelosuppression was due partially to stimulation by IL-6, because IL-6 is strongly suspected to stimulate G-CSF production through its effect on non-hematopoietic cells. n summary, both serum IL-6 and G-CSF levels were elevated during chemotherapy-induced myelosuppression and their serum levels correlated significantly. Furthermore, the more severe the myelosuppression, the higher the serum G-CSF level. Serum SCF, IL-la, IL-3 and GM-CSF appeared to play less important roles in myelosuppression than IL-6 and G-CSF.
